Compare AbCellera Biologics Inc (ABCL) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Vertiv Holdings Co — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while Vertiv Holdings Co trades at $313.58 (market cap $117.38B). The key difference: Vertiv Holdings Co is far larger — about 49.9× AbCellera Biologics Inc's market cap, and Vertiv Holdings Co pays a 0.08% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | VRT | |
|---|---|---|
Market Cap | $2.35B | $117.38B |
Sector | Health | Technology |
52-Week High | $8.12 | $376.23 |
52-Week Low | $2.78 | $120.72 |
Enterprise Value | $1.99B | $118.14B |
Dividend Yield | — | 0.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Vertiv Holdings (VRT) trades at $318.47, up 5.97% with strong bullish momentum. The stock shows robust fundamentals with Q1 2026 EPS beating estimates at $1.17 versus $1.00 expected, continuing a pattern of earnings outperformance. Technical indicators signal bullish momentum with the current price near pivot point resistance at $319. The company benefits from AI infrastructure demand, supported by recent manufacturing expansion in Malaysia and strategic acquisitions enhancing its data center portfolio.
Outlook remains positive with 94.7% analyst buy ratings and a $395.23 consensus price target implying 24% upside. Key risks include premium valuation multiples (P/E 80.02) and execution challenges in scaling operations. The AI infrastructure boom presents significant growth opportunity, though investors should monitor competitive pressures and macroeconomic conditions affecting data center spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
